Patents Assigned to ADIMAB, LLC
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20230287141
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Applicants: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
  • Antibodies against BACE1 and use thereof for neural disease immunotherapy
    Patent number: 11746160
    Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: September 5, 2023
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus
  • Anti-coagulation factor XI antibodies
    Patent number: 11661460
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: May 30, 2023
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • ANTI-IL-27 ANTIBODIES AND USES THEREOF
    Publication number: 20230042258
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
    Type: Application
    Filed: April 6, 2022
    Publication date: February 9, 2023
    Applicants: Surface Oncology, Inc., Adimab LLC
    Inventors: Jonathan HILL, Scott CHAPPEL, Michael GLADSTONE, Bianka PRINZ, Andrew LAKE, Christine MILLER, Kerry WHITE, Jing HUA, Pamela M. HOLLAND, Matthew RAUSCH, Devapregasan MOODLEY
  • Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
    Patent number: 11542330
    Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: January 3, 2023
    Assignee: Adimab, LLC
    Inventors: Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
  • Anti-coagulation factor XI antibodies
    Patent number: 11512142
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 29, 2022
    Assignees: Merck Sharp & Dohme LLC, Adimab LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • Anti-respiratory syncytial virus antibodies, and methods of their generation and use
    Patent number: 11485775
    Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: November 1, 2022
    Assignee: Adimab, LLC
    Inventor: Laura M. Walker
  • Anti-coagulation factor XI antibodies
    Patent number: 11485794
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 1, 2022
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • Anti-coagulation factor XI antibodies
    Patent number: 11479615
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 25, 2022
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • Anti-respiratory syncytial virus antibodies, and methods of their generation and use
    Patent number: 11479600
    Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as nucleic acid sequences encoding such antibodies, methods for their identification, isolation, generation, and methods for their preparation and use are provided.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: October 25, 2022
    Assignee: Adimab, LLC
    Inventor: Laura M. Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11407817
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: August 9, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Z. Wec, Laura Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11407816
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: August 9, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Polyclonal mixtures of antibodies, and methods of making and using them
    Patent number: 11390964
    Abstract: A method of broadening epitopic coverage of an antigen of interest, wherein a first sample of the antigen of interest is contacted with a first plurality of host cells collectively expressing a first library of antibodies. Host cells expressing antibodies that bind to the antigen are then collected from among the first plurality of host cells, and a composition is prepared comprising a polyclonal mixture of antibodies expressed by these host cells. A second sample of the antigen of interest is then contacted with an aliquot of the prepared composition and a second plurality of host cells collectively expressing a second library of antibodies. Host cells expressing antibodies that bind to the second sample of the antigen are then collected from among the second plurality of host cells.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: July 19, 2022
    Assignee: Adimab, LLC
    Inventors: Laura M. Walker, Eric Krauland, Karl Dane Wittrup
  • Anti-IL-27 antibodies and uses thereof
    Patent number: 11332524
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: May 17, 2022
    Assignees: Surface Oncology, Inc., Adimab LLC
    Inventors: Jonathan Hill, Scott Chappel, Michael Gladstone, Bianka Prinz, Andrew Lake, Christine Miller, Kerry White, Jing Hua, Pamela M. Holland, Matthew Rausch, Devapregasan Moodley
  • Anti-respiratory syncytial virus antibodies, and methods of their generation and use
    Patent number: 11312761
    Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 26, 2022
    Assignee: Adimab, LLC
    Inventor: Laura M. Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11254732
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 22, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11242379
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 8, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Monoclonal antibodies and cocktails for treatment of Ebola infections
    Patent number: 11242378
    Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: February 8, 2022
    Assignees: MAPP BIOPHARMACEUTICAL, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, ADIMAB, LLC
    Inventors: Zachary A. Bornholdt, Larry Zeitlin, Kartik Chandran, Anna Wec, Laura Walker
  • Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy
    Publication number: 20210206877
    Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders
    Type: Application
    Filed: December 7, 2020
    Publication date: July 8, 2021
    Applicants: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus
  • Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
    Patent number: 11008403
    Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 18, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus, Yin Zhang, Joy Yu Zuchero, Jessica Couch, Mark S Dennis, James A Ernst, Gregory A Lazar